Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

CHOLESTYRAMINE POWDER

cholestyramine powder for suspension
$0.0972per GM

Strength

4 g/8.78g

Manufacturer

Ascend Laboratories, LLC

NDC

67877029837

Classification

Generic

Dosage Form

POWDER, FOR SUSPENSION

Route

ORAL

Last Updated

3/18/2026

Active Ingredients

CHOLESTYRAMINE

Approval Type

Generic (ANDA)

FDA Application

ANDA211856

On Market Since

10/20/2021

Pharmacological Classes

Bile Acid Sequestrant
Bile-acid Binding Activity

Price History

1W

0.0%

1M

0.0%

3M

+2.2%

6M

+10.8%

1Y

+9.1%

3Y

+25.1%

5Y

N/A

All

-11.2%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

CHOLESTYRAMINE POWDER
Generic
24658026693•PuraCap Laboratories LLC
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
24658026697•PuraCap Laboratories LLC
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
27241013451•Ajanta Pharma USA Inc.
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
42806026793•Epic Pharma LLC
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
42806026797•Epic Pharma LLC
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
49884046566•Endo USA Inc.
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
62135000856•Chartwell RX LLC
$0.0948
per GM
CHOLESTYRAMINE POWDER
Generic
68382052842•Zydus Pharmaceuticals (USA) Inc.
$0.0948
per GM
CHOLESTYRAMINE LIGHT POWDER
Generic
24658027197•PuraCap Laboratories LLC
$0.1028
per GM
CHOLESTYRAMINE LIGHT POWDER
Generic
42806027193•Epic Pharma LLC
$0.1028
per GM

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy